early access programmes | pharmaphorum

Skip to main content

Thursday 5 March 2026

BlueSky linkedin youtube

header links

Get Newsletters
Media Kit

Pharmaphorum menu first category

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
Spotlight on
Events

close

SECTION

News
Views & Analysis
Deep Dive
Webinars
Podcasts
Videos
White Papers
Events

Channels

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

Channels

Sales & Marketing
R&D
Digital
Market Access
Oncology
Patients
Spotlight On

SUB NAVIGATION

Live Coverage
Partner Content
About us
Work for us
Contribute
Contact us
Advertise

Newsletters and Deep Dive digital magazine

youtube linkedin BlueSky

early access programmes

Market Access

pharmaphorum Episode 200a - Suzanne Aitken, Clinigen

MAPs, EAPs, and patient access: Suzanne Aitken on the challe...

Suzanne Aitken, SVP of managed access at Clinigen, discussing the role of managed access programmes in the current pharmaceutical landscape.

Market Access

pharmaphorum podcast Episode 179a - Cen Zorlular, Er-Kim Pharmaceuticals

EAPs: Market access outside of the US and Western Europe

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Cem Zorlular, CEO of Er-Kim Pharmaceuticals about early access programmes.

Market Access

two pathways

NICE and the controversy over a ‘clinically distinct disease...

Payers worldwide are struggling with a new generation of precision medicines that come with a hefty price tag.

Market Access

real-world data

Transformative trends with real-world data from early access...

The complex and changing needs of patients with life-threatening conditions has led many health authorities to introduce early access programmes.

Editor's Picks

US lawmakers take FDA to task over rare diseases record

Gilead buys cell therapy partner Arcellx for up to $7.8bn

What next for pharma as SCOTUS strikes down Trump tariffs?

Novo Nordisk to cut GLP-1 prices in tough US market

UK spurs prescribing of obesity jab Mounjaro with GP bonus

News

Five projects share £100m UK-US Cancer Grand Challenges fund

Five projects share £100m UK-US Cancer Grand Challenges fund

Five scientific teams will receive up to £20m each in a new round of funding under the UK and US Cancer Grand Challenges initiative.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/register.png

Sales & Marketing

Using AI-driven synthetic personas to take your insights further

Sponsored

Using AI-driven synthetic personas to take your insights fur...

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.

Pharmaphorum Menu

Digital
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Market Access
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Oncology
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Patients
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
R&D
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Sales & Marketing
- News
- Views & Analysis
- Deep Dive
- Webinars
- Podcasts
- Video
- White Papers
- Event
Spotlight on

Sign up for email newsletters and Deep Dive

Get Newsletters

youtube linkedin BlueSky

About us Advertising Contact us

Contribute Cookie Policy Privacy Policy

Terms & Conditions Work for us

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company

The rights of trademark owners are acknowledged. Website and content copyright © 2009-2026, pharmaphorum media limited or its licensors; all rights reserved. pharmaphorum – an EVERSANA company